Claritas Pharmaceuticals Inc V.CLAS

Primary Symbol: V.CLAS.H Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

<< Previous

Bullboard Posts

Next >>

Post by Red~Oneon Sep 23, 2022 9:44am

264 Views

Post# 34981440

Alternate theory of Farewell

After choosing to delay the planned 2020 launch of the product worldwide, the management team further refined and developed their wondrous and versatile product in preparation to initiate the delayed launch in the fourth quarter of (choose year here) and is now emerging from stealth mode going forward.

"It will be the best product ever, no one has ever seen a product like this before, it is the best product ever."

<< Previous

Bullboard Posts

Next >>

Morning Market Outlook for May 24, 2024